当前位置: X-MOL 学术ACS Med. Chem. Lett. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Mixed Aryl Phosphonate Prodrugs of a Butyrophilin Ligand
ACS Medicinal Chemistry Letters ( IF 4.2 ) Pub Date : 2017-08-16 00:00:00 , DOI: 10.1021/acsmedchemlett.7b00245
Benjamin J. Foust 1 , Michael M. Poe 2 , Nicholas A. Lentini 1 , Chia-Hung Christine Hsiao 2 , Andrew J. Wiemer 2, 3 , David F. Wiemer 1, 4
Affiliation  

Studies of aryl phosphonate derivatives of a butyrophilin 3A1 ligand have resulted in identification of a potent stimulant of Vγ9 Vδ2 T cells. This compound, a mixed ester bearing one pivaloyloxymethyl substituent and one 1-naphthyl ester displayed an EC50 of 0.79 nM as a stimulant of T cell proliferation, and a 9.0 nM EC50 in an assay designed to measure interferon gamma production. In both assays, this is the most potent butyrophilin ligand prodrug yet reported, and thus it should be a valuable tool for studies of T cell function. Furthermore, mixed aryl/acyloxyalkyl esters may represent a new class of phosphonate prodrugs with high efficacy.

中文翻译:

Butyrophilin配体的混合芳基膦酸酯前药

对butyrophilin 3A1配体的芳基膦酸酯衍生物的研究已导致鉴定出有效的Vγ9Vδ2T细胞刺激物。该化合物是带有一个新戊酰氧基甲基取代基和一个1-萘基酯的混合酯,在刺激T细胞增殖的试验中,EC 50为0.79 nM,刺激T细胞增殖为9.0 nM EC 50。在这两种测定中,这都是迄今报道的最有效的嗜酪蛋白配体前体药物,因此,它应该是研究T细胞功能的有价值的工具。此外,混合的芳基/酰氧基烷基酯可以代表具有高功效的一类新的膦酸酯前药。
更新日期:2017-08-16
down
wechat
bug